trial

Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in Schizophrenia

NCTId NCT03132571
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 5 (actual)
Sponsored by Yale University
Primary completion 2018-07-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
5 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2017-06-01
Primary completion
2018-07-31
Eligibility
ALL · 18 Years · 75 Years

Interventions & indications

Drugs
NaltrexoneBupropion

Sponsors

Yale UniversityLead Sponsor

Investigators

1
Cenk Tek, MDPrincipal Investigator

Sites

1 total
New Haven, United States

Linked catalysts

1
Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in Schizophrenia — primary completion2018-07-31

Facts & assertions

4 sourced
Enrollment
5
Phase
PHASE2
Primary Completion Date
2018-07-31
Status
TERMINATED
relationships
The graph out of here
drug
Naltrexone
drug
Bupropion
drug
lead_sponsor
Yale University
company
indication
Obesity
indication
Diabetes Mellitus, Type 2
indication
Diabetes Mellitus
indication
investigator
Cenk Tek, MD
person